Insulatard Flexpen (Insulin Human)

Insulin human mimics the action of natural pancreatic insulin. It binds to insulin receptors on muscle, fat and liver cells, stimulating glucose uptake and storage while inhibiting hepatic glucose production. This dual action reduces circulating glucose and supplies cells with energy.

The dose of Insulatard Flexpen is individualized. A qualified prescriber determines the amount, timing and frequency based on the patient’s blood‑glucose readings, diet, activity level and overall treatment plan. No standard regimen is provided in public information.

Insulin human is classified as a pregnancy‑category B drug in many regions, meaning it may be used when the potential benefit justifies the potential risk. Breastfeeding mothers should consult their healthcare provider, as insulin is present in small amounts in milk but is generally considered compatible with nursing.

To request Insulatard Flexpen, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping options and necessary import documentation.

Insulatard Flexpen (NPH) has a longer onset and duration than rapid‑acting insulins but a shorter and more variable profile than newer basal analogues such as insulin glargine or insulin detemir. NPH may require twice‑daily dosing, whereas analogues often allow once‑daily administration with a flatter glucose‑lowering curve.

Store the pen at 2‑8 °C (refrigerated) in its original carton, protected from light. Do not freeze or shake the pen. Once in use, it may be kept at controlled room temperature (up to 30 °C) for a maximum of 28 days, as specified in the product label.

Insulatard Flexpen is administered subcutaneously using the pre‑filled pen device. The injection site should be rotated among the abdomen, thigh or upper arm. Patients should follow the pen’s instructions for dose setting, needle attachment and disposal, and always inject into clean, dry skin.

The most serious risks include severe hypoglycaemia, which can cause loss of consciousness or seizures, and allergic reactions ranging from rash to anaphylaxis. Rarely, insulin antibodies may develop, altering insulin action and causing unpredictable glucose control.

Insulatard Flexpen is contraindicated in individuals with a known hypersensitivity to insulin human or any excipients in the formulation. Patients with severe hypoglycaemia unawareness or those who cannot reliably monitor blood glucose should use it only under close medical supervision.